SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):March 12, 2004
--------------
A.P. PHARMA, INC.
------------------------------------------------------
(Exact name of Registrant as specified in its charter)
DELAWARE 1-16109 94-2875566
- ---------------------------- ---------- -----------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
123 SAGINAW DRIVE, REDWOOD CITY, CALIFORNIA 94063
--------------------------------------------------------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code:
(650) 366-2626
--------------
N/A
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
INFORMATION TO BE INCLUDED IN THE REPORT
ITEM 7. Financial Statements, Pro Forma Financial Information
and Exhibits.
(c) Exhibits
99.1 Press release dated March 12, 2004.
ITEM 12. Results of Operations and Financial Condition.
The following information is disclosed pursuant to Item 12 of
Form 8-K:
On March 12, 2004, the Registrant issued a press release
announcing its financial results for the fiscal quarter and year
ended December 31, 2003. The press release is attached hereto as
Exhibit 99.1 and incorporated herein by reference.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
A.P. PHARMA, INC.
Date: March 12, 2004 By: /S/ Michael O'Connell
------------------ ----------------------
Michael P. J. O'Connell,
President and Chief
Executive Officer
EXHIBIT INDEX
99.1 Press release dated March 12, 2004.
(continued from previous page)